Clinical trial
Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
NCT00254735 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00254735 |
|---|---|
| Title | Quetiapine Augmentation in Severe Obsessive Compulsive Disorder |
| Official title | Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obsessive Compulsive Disorder |
| Intervention type | Drug |
| Interventions | quetiapine fumarate, SSRI/Clomipramine |
| Enrollment | 44 |
| Start date | Apr 1, 2002 |
| Completion | Mar 1, 2006 |
| First posted | Nov 17, 2005 |
| Last update posted | Dec 18, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: